Here, we show that the combination of an approved nutraceutical, the epigenetic modulator SAM, with an anti-PD-1 antibody displayed strong anticancer effects against B16 cells, the most commonly used preclinical syngeneic mouse model of advanced melanoma. The gene discussed is PDCD1; the disease is melanoma.